TOP TEN perturbations for 38550_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38550_at
Selected probe(set): 215148_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38550_at (215148_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):2.654479Number of Samples:2 / 3
| Experimental | glioma study 17 (anaplastic astrocytoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
heat shock study 3 / untreated THP-1 cell sample
Relative Expression (log2-ratio):2.470498Number of Samples:3 / 3
| Experimental | heat shock study 3 |
| Cultured THP-1 mononuclear cells were treated with heat shock (43°C) for 1 hour followed by a 4 hour recovery period at 37°C. | |
| Control | untreated THP-1 cell sample |
| Cultured THP-1 mononuclear cells were cultured in basal growth media at 37°C. |
heat shock study 1 (LPS) / untreated THP-1 cell sample
Relative Expression (log2-ratio):2.409275Number of Samples:3 / 3
| Experimental | heat shock study 1 (LPS) |
| Cultured THP-1 mononuclear cells were treated with heat shock (43°C; 1h) and lipopolysaccharide (1ug/ml; 4h). | |
| Control | untreated THP-1 cell sample |
| Cultured THP-1 mononuclear cells were cultured in basal growth media at 37°C. |
glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):2.2181034Number of Samples:3 / 3
| Experimental | glioma study 17 (glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
male infertility study 1 (juvenile; Ad-) / normal testicular lobules tissue (mJS10)
Relative Expression (log2-ratio):1.8764162Number of Samples:2 / 8
| Experimental | male infertility study 1 (juvenile; Ad-) |
| Human testicular lobules biopsy samples isolated from prepubescent patients with undescended testes. Testes of these children contained very low level of A-dark (Ad-) spermatogonial cells. | |
| Control | normal testicular lobules tissue (mJS10) |
| Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10). |
prostate cancer study 8 (ptasc) / prostate cancer study 8 (psfmc)
Relative Expression (log2-ratio):1.8556404Number of Samples:2 / 5
| Experimental | prostate cancer study 8 (ptasc) |
| CD90+ FACS sorted prostate tumor-associated stromal cell (ptasc) samples from patients with primary prostate cancer collected after radical prostatectomy. | |
| Control | prostate cancer study 8 (psfmc) |
| CD49a+ FACS sorted prostate stromal fibromuscular cell (psfmc) samples from patients with primary prostate cancer collected after radical prostatectomy. |
endometriosis study 6 (minimal/mild endo.; pro. MCP) / normal endometrium tissue (pro. MCP)
Relative Expression (log2-ratio):1.692543Number of Samples:12 / 20
| Experimental | endometriosis study 6 (minimal/mild endo.; pro. MCP) |
| Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the proliferative menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | normal endometrium tissue (pro. MCP) |
| Normal endometrial tissue samples from women collected in the proliferative menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. |
B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)
Relative Expression (log2-ratio):1.6660938Number of Samples:4 / 4
| Experimental | B-CLL study 11 (rolipram) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
| Control | rolipram study 4 (normal B-cell; 20uM) |
| MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
uterine/pelvic pathology study 2 (pro. MCP) / normal endometrium tissue (pro. MCP)
Relative Expression (log2-ratio):1.6594076Number of Samples:15 / 20
| Experimental | uterine/pelvic pathology study 2 (pro. MCP) |
| Endometrial tissue samples collected from women with uterine/pelvic pathology in the proliferative menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | normal endometrium tissue (pro. MCP) |
| Normal endometrial tissue samples from women collected in the proliferative menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. |
endometriosis study 6 (minimal/mild endo.; mid-se MCP) / normal endometrium tissue (mid-se MCP)
Relative Expression (log2-ratio):1.639533Number of Samples:9 / 8
| Experimental | endometriosis study 6 (minimal/mild endo.; mid-se MCP) |
| Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the mid-secretory menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | normal endometrium tissue (mid-se MCP) |
| Normal endometrial tissue samples from women collected in the mid-secretory menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. |